专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5880111A Therapeutic derivations of diphosphonates 失效
标题翻译：二膦酸盐的治疗衍生物
公开(公告)号：US5880111A
公开(公告)日：1999-03-09
申请号：US478245
申请日：1995-06-07
申请人： Dan Farcasiu , John F. Hartmann , Pal Herczegh , Ferenc J. Sztaricskai
发明人： Dan Farcasiu , John F. Hartmann , Pal Herczegh , Ferenc J. Sztaricskai
IPC分类号： C07D499/00 , C07D501/00 , C07F9/40 , C07F9/60 , C07F9/6558 , C07F9/6561 , A61K31/43 , A61K31/495 , A61K31/545 , C07D241/04 , C07D265/36 , C07D499/88 , C07F9/02
CPC分类号： C07D501/00 , C07D499/00 , C07F9/4025 , C07F9/60 , C07F9/65583 , C07F9/6561 , C07F9/65613
摘要： Novel chemotherapeutic agents having utility in treating infectious diseases such as periodontal disease, certain urinary tract infections, and infectious urinary tract stones, are obtained by combining chemically a diphosphonate compound with a therapeutic agent effective against the foregoing diseases.
摘要翻译：通过将二膦酸盐化合物与对上述疾病有效的治疗剂进行化学组合，可以获得用于治疗传染病如牙周病，某些尿路感染和感染性尿路结石的新型化学治疗剂。

2. 发明授权

US06333424B1 Therapeutic derivatives of diphosphonates 失效
标题翻译：二膦酸盐的治疗衍生物
公开(公告)号：US06333424B1
公开(公告)日：2001-12-25
申请号：US09269974
申请日：1999-04-08
申请人： Pal Herczegh , John F. Hartmann , Arpad Kovacs , Ferenc J. Sztaricskai , Miklos Hornyak
发明人： Pal Herczegh , John F. Hartmann , Arpad Kovacs , Ferenc J. Sztaricskai , Miklos Hornyak
IPC分类号： C07F902
CPC分类号： C07F9/65583 , C07F9/3865 , C07F9/4043 , C07F9/6561
摘要： Compounds having utility in achieving the foregoing objects of the invention are prepared by reacting a 2,2-bis-(disubstituted-phosphoryl)-ethylsulfanyl-acetic acid compound with a pharmaceutically active chemical entity effective to treat the underlying disease state or with non-pharmaceutical entities such as pesticides, insecticides, fungicides or poisons for vermin.
摘要翻译：通过使2,2-双（二取代的 - 磷酰基） - 乙基硫烷基 - 乙酸化合物与有效治疗潜在疾病状态的药物活性化学实体或非天然存在的化合物反应来制备用于实现本发明上述目的的化合物，制药实体，如农药，杀虫剂，杀真菌剂或害虫等。

3. 发明授权

US5854227A Therapeutic derivatives of diphosphonates 失效
标题翻译：二膦酸盐的治疗衍生物
公开(公告)号：US5854227A
公开(公告)日：1998-12-29
申请号：US473787
申请日：1995-06-07
申请人： John F. Hartmann , Dan Farcasiu
发明人： John F. Hartmann , Dan Farcasiu
IPC分类号： A61B5/042 , C07D499/00 , C07D501/00 , C07F9/38 , C07F9/40 , C07F9/60 , C07F9/6509 , C07F9/6533 , C07F9/6539 , C07F9/6558 , C07F9/6561 , A61K31/43 , A61K31/545 , A61K31/495 , C07F9/02
CPC分类号： A61B5/0422 , C07D499/00 , C07D501/00 , C07F9/3869 , C07F9/3873 , C07F9/404 , C07F9/60 , C07F9/650958 , C07F9/65335 , C07F9/6539 , C07F9/65583 , C07F9/6561 , C07F9/65613 , A61B5/4504 , A61B5/4547
摘要： Novel chemotherapeutic agents having utility in treating infectious diseases such as periodontal disease, certain urinary tract infections, infectious urinary tract stones, and bone cancer, are obtained by combining chemically a diphosphonate compound with a therapeutic agent effective against the foregoing diseases.
摘要翻译：通过将二膦酸酯化合物与对上述疾病有效的治疗剂化学结合，可获得用于治疗传染病如牙周病，某些尿路感染，感染性尿路结石和骨癌的新型化学治疗剂。

4. 发明授权

US5900410A Monotherapy of peptic ulcers and gastritis 失效
标题翻译：消化性溃疡和胃炎的单药治疗
公开(公告)号：US5900410A
公开(公告)日：1999-05-04
申请号：US909896
申请日：1997-08-12
申请人： John F. Hartmann
发明人： John F. Hartmann
IPC分类号： A61K33/00 , A61K33/06 , A61K31/675 , C07F9/6558 , C07F9/6561
CPC分类号： A61K47/48084 , A61K33/00 , A61K33/06
摘要： The present invention is directed to compositions, methods and kits for treating areas of H. pylori infection in the GI tract. The active ingredient is an antibiotic-bisphosphonate adduct wherein the antibiotic is selected for its ability to eradicate H. pylori. Other components include a salt of a divalent cation that is insolubilized in vivo at alkaline pH, and optionally a substrate from which the enzyme urease liberates NH.sub.3.
摘要翻译：本发明涉及用于治疗胃肠道幽门螺杆菌感染区域的组合物，方法和试剂盒。活性成分是抗生素 - 双膦酸盐加合物，其中选择抗生素以消除幽门螺杆菌的能力。其它组分包括在碱性pH下在体内不溶解的二价阳离子盐，以及任选的脲酶释放NH 3的底物。

5. 发明申请

US20090180966A1 Cancer cell diagnosis by targeting delivery of nanodevices 有权
标题翻译：通过靶向纳米设备的递送进行癌细胞诊断
公开(公告)号：US20090180966A1
公开(公告)日：2009-07-16
申请号：US12315951
申请日：2008-12-08
申请人： Janos Borbely , Magdolna Bodnar , John F. Hartmann , Istvan Hajdu , Jozsef Kollar , Gyorgy Vamosi
发明人： Janos Borbely , Magdolna Bodnar , John F. Hartmann , Istvan Hajdu , Jozsef Kollar , Gyorgy Vamosi
IPC分类号： A61K9/14 , A61P43/00
CPC分类号： A61K31/519 , A61K31/7088 , A61K49/1824 , B82Y5/00 , Y10S977/773 , Y10S977/93
摘要： Macromolecular contrast agents for magnetic resonance imaging are described. Biomolecules and their modified derivatives form stable complexes with paramagnetic ions thus increasing the molecular relaxivity of carriers. The synthesis of biomolecular based nanodevices for targeted delivery of MRI contrast agents are described. Nanoparticles (NP) have been constructed by self-assembling of chitosan (CHIT) as polycation and poly-gamma glutamic acids (PGA) as polyanion. NP's are capable of Gd-ion uptake forming a particle with suitable molecular relaxivity. Folic acid (FA) is linked to the NP's to produce NP-FA bioconjugates that can be used for targeted in vitro delivery to a human cancer cell line.
摘要翻译：描述了用于磁共振成像的大分子造影剂。生物分子及其修饰的衍生物与顺磁离子形成稳定的络合物，从而增加载体的分子弛豫性。描述了用于靶向递送MRI造影剂的基于生物分子的纳米装置的合成。纳米颗粒（NP）已经通过壳聚糖（CHIT）作为聚阳离子和聚-γ谷氨酸（PGA）作为聚阴离子自组装而构建。 NP能够进行Gd离子吸收，形成具有合适分子弛豫性的颗粒。叶酸（FA）与NP连接以产生可用于靶向体外递送至人癌细胞系的NP-FA生物缀合物。

6. 发明申请

US20090018266A1 Preparation of hydrophilic nanoparticles by copolymerization of mono and divinyl monomers in micellar solution 审中-公开
标题翻译：通过在胶束溶液中共聚单和二乙烯基单体制备亲水性纳米颗粒
公开(公告)号：US20090018266A1
公开(公告)日：2009-01-15
申请号：US11598548
申请日：2006-11-13
申请人： Janos Borbely , John F. Hartmann
发明人： Janos Borbely , John F. Hartmann
IPC分类号： C08F30/02 , C08F2/24
CPC分类号： C08F2/24 , C08F220/06 , C08F222/1006 , C08F226/10 , C08F230/02
摘要： The present invention relates to the preparation of hydrophilic nanoparticles and in particular hydrophilic nanoparticles that are biocompatible. Free radical monovinyl-divinyl monomer copolymerization/cross-linking reactions of water-soluble, monovinyl N-vinyl-2-pyrrolidone (NVP) with a bi-unsaturated divinyl, comonomer (poly{ethylene glycol}dimethacrylate) (PEGDMA), has been found to yield hydrophilic nanoparticles (NPs). These nanoparticles are built from three-dimensional nanopolymer networks. In the polymers' synthesis the composition of the monomers, and the total monomer concentration were varied. The characteristics of copolymers were determined by nuclear magnetic resonance spectroscopy (NMR), Fourier transform infrared (FTIR) and elemental analysis. Particle size and morphology of nanoparticles were confirmed by dynamic light scattering (DLS), transmission electron microscope (TEM) and scanning electron microscope (SEM) methods. In the present invention hydrophilic polymers can be used in micellar polymerization to create hydrophilic nanoparticles.
摘要翻译：本发明涉及亲水性纳米颗粒的制备，特别是生物相容的亲水性纳米颗粒。已经将水溶性单乙烯基N-乙烯基-2-吡咯烷酮（NVP）与双不饱和二乙烯基共聚单体（聚{乙二醇}二甲基丙烯酸酯）（PEGDMA））的自由基单乙烯基 - 二乙烯基单体共聚/交联反应发现产生亲水性纳米颗粒（NP）。这些纳米颗粒由三维纳米聚合物网络构建。在聚合物的合成中，单体的组成和总单体浓度是变化的。通过核磁共振光谱（NMR），傅立叶变换红外（FTIR）和元素分析测定共聚物的特性。通过动态光散射（DLS），透射电子显微镜（TEM）和扫描电子显微镜（SEM）方法证实了纳米颗粒的粒径和形貌。在本发明中，亲水性聚合物可用于胶束聚合以产生亲水性纳米颗粒。

7. 发明授权

US4798821A Antihypertensive therapy for diabetics 失效
标题翻译：糖尿病患者抗高血压治疗
公开(公告)号：US4798821A
公开(公告)日：1989-01-17
申请号：US20611
申请日：1987-03-02
申请人： John F. Hartmann
发明人： John F. Hartmann
IPC分类号： A61K38/00 , C07K14/655 , A61K37/02 , C07K7/26
CPC分类号： C07K14/6555 , A61K38/00 , Y10S514/806 , Y10S930/16 , Y10S930/26 , Y10S930/27
摘要： Process and compositions for lowering blood pressure in diabetic by employing a cyclopeptide compound is described.
摘要翻译：描述了通过使用环肽化合物降低糖尿病患者血压的方法和组合物。

8. 发明申请

US20080193547A1 Polymeric nanoparticles by ion-ion Interactions 审中-公开
标题翻译：聚合物纳米粒子通过离子 - 离子相互作用
公开(公告)号：US20080193547A1
公开(公告)日：2008-08-14
申请号：US12005643
申请日：2007-12-27
申请人： Janos Borbely , Magdolna Bodnar , Istvan Hajdu , John F. Hartmann
发明人： Janos Borbely , Magdolna Bodnar , Istvan Hajdu , John F. Hartmann
IPC分类号： A61K9/16 , A61K31/7088 , A61K31/519
CPC分类号： A61K31/519 , A61K9/5146 , A61K9/5161 , A61K31/7088 , A61K47/6929 , A61K47/6933 , A61K47/6939 , A61K49/12 , A61K49/146 , A61K49/1818 , A61K49/1878 , B82Y5/00
摘要： The present invention relates to biocompatible and biodegradable, stimuli sensitive, polymeric nanoparticles, which are formed by ion-ion interaction in aqueous media. Synthetic and biological macromolecules with ionizable functional groups are capable of forming nanoparticles whose size and surface properties are sensitive to environmental factors such as pH, temperature and salt concentration. Nanodevices made from these nanoparticles are designed for therapeutic applications included but not limited to use as drug carriers and/or used as contrast agents in MRI diagnosis and the like. The adjustable size of the nanodevices and their stimuli sensitivity allows specific delivery applications. Thus, these nanosystems are potential carrier tools for delivery of active ingredients such as drugs, as well as DNA, RNA, siRNA for cosmetics, pharmaceutical applications, etc.
摘要翻译：本发明涉及通过在水介质中离子 - 离子相互作用而形成的生物相容性和可生物降解的刺激敏感的聚合物纳米颗粒。具有可离子化官能团的合成和生物大分子能够形成尺寸和表面性质对环境因素如pH，温度和盐浓度敏感的纳米颗粒。由这些纳米颗粒制成的纳米装置设计用于治疗应用，包括但不限于用作药物载体和/或用作MRI诊断等中的造影剂。纳米器件的可调节尺寸及其刺激灵敏度允许特定的输送应用。因此，这些纳米系统是用于递送活性成分如药物的潜在载体工具，以及用于化妆品的DNA，RNA，siRNA，药物应用等。

9. 发明申请

US20080160096A1 Polymeric nanoparticles by ion-ion interactions 审中-公开
标题翻译：通过离子 - 离子相互作用的聚合物纳米颗粒
公开(公告)号：US20080160096A1
公开(公告)日：2008-07-03
申请号：US11881831
申请日：2007-07-27
申请人： Janos Berbely , Magdolna Bodnar , Istvan Hajdu , John F. Hartmann , Zsolt Keresztessy , Laszlo Nagy , Gyorgy Vamosi
发明人： Janos Berbely , Magdolna Bodnar , Istvan Hajdu , John F. Hartmann , Zsolt Keresztessy , Laszlo Nagy , Gyorgy Vamosi
IPC分类号： A61K9/50
CPC分类号： A61K9/5138 , A61K9/5015 , A61K9/5026 , A61K9/5036 , A61K9/5146 , A61K9/5161 , A61K9/5192 , C12N15/87
摘要： The present invention relates to biocompatible and biodegradable stimuli-sensitive polymeric nanoparticles, which were formed by ion-ion interaction in aqueous media. Synthetic and biological macromolecules with ionizable functional groups are capable of forming nanoparticles whose size and surface properties are sensitive to environmental influences such as pH, temperature and salt concentration. Nanodevices are designed for therapeutic applications as drug and nucleic acid carriers, and/or for MRI diagnosis as contrast agents. These nanodevices are designed for therapeutic applications as targeted drug carriers. Additionally, they can be used as contrast agents for MRI diagnosis. These nanosystems are also potential carriers for delivery of active ingredients as DNA, RNA, short interfering RNA (siRNA), antisense oligonucleotides (AS-ON), and triple helix forming oligonucleotides (TFO) etc. for pharmaceutical applications. Their adjustable size offers yet another advantage.
摘要翻译：本发明涉及生物相容性和生物可降解的刺激性敏感的聚合物纳米粒子，其通过在水性介质中的离子 - 离子相互作用而形成。具有可离子化官能团的合成和生物大分子能够形成尺寸和表面性质对pH，温度和盐浓度等环境影响敏感的纳米颗粒。纳米设备设计用作药物和核酸载体的治疗应用，和/或作为造影剂的MRI诊断。这些纳米设备被设计用作靶向药物载体的治疗应用。此外，它们可以用作MRI诊断的造影剂。这些纳米系统也是作为药物应用的DNA，RNA，短干扰RNA（siRNA），反义寡核苷酸（AS-ON）和三螺旋形成寡核苷酸（TFO）等递送活性成分的潜在载体。它们的可调节尺寸提供了另一个优点。

10. 发明授权

US5955054A Diagnostic assay for localizing H. pylori 失效
标题翻译：用于定位幽门螺杆菌的诊断测定
公开(公告)号：US5955054A
公开(公告)日：1999-09-21
申请号：US69124
申请日：1998-04-29
申请人： John F. Hartmann
发明人： John F. Hartmann
IPC分类号： A61K51/12 , A61K51/00 , A61M36/14
CPC分类号： A61K51/12
摘要： An object of the present invention is to provide a non-invasive method to detect H. pylori within the stomach and duodenum. Another object is to provide a non-invasive method to localize this organism within the stomach and duodenum. A further object is to provide a kit containing the reagents for carrying out the diagnostic assay of the present invention.
摘要翻译：本发明的目的是提供一种在胃和十二指肠内检测幽门螺杆菌的非侵入性方法。另一个目的是提供一种在胃和十二指肠内定位该生物体的非侵入性方法。另一个目的是提供一种包含用于进行本发明的诊断测定的试剂的试剂盒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式